Trials / No Longer Available
No Longer AvailableNCT02097251
An Open-Label Treatment Protocol With UX003 rhGUS Enzyme Replacement Therapy for an Advanced Stage MPS 7 Patient
An Open-Label Treatment Protocol With UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy for an Advanced Stage Mucopolysaccharidosis Type 7 (MPS 7) Patient
- Status
- No Longer Available
- Phase
- —
- Study type
- Expanded Access
- Enrollment
- —
- Sponsor
- Joyce Fox · Academic / Other
- Sex
- Male
- Age
- —
- Healthy volunteers
- —
Summary
Emergency access granted to treat a single patient with advanced Mucopolysaccharidosis Type 7 with UX003 Recombinant Human Beta-glucuronidase (rhGUS) Enzyme Replacement Therapy via IV administration every other week (QOW) for up to 144 weeks.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | UX003 | Open Label |
Timeline
- First posted
- 2014-03-27
- Last updated
- 2017-02-06
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02097251. Inclusion in this directory is not an endorsement.